[144] Bicara Therapeutics Inc. SEC Filing
Bicara Therapeutics (BCAX) filed a Form 144 notice disclosing a proposed sale of 22,000 common shares, acquired the same day by exercising stock options. The broker listed is UBS Financial Services and the shares are to be sold on Nasdaq with an approximate aggregate market value of $405,900. The filing reports 54,562,841 shares outstanding and indicates the proposed sale date as 10/09/2025. No securities were reported sold in the prior three months. The filer attests they are not aware of undisclosed material adverse information and notes exercise payment was made in cash.
Bicara Therapeutics (BCAX) ha presentato una Form 144 nota che rivela una proposta di vendita di 22.000 azioni ordinarie, acquisite lo stesso giorno eseguendo opzioni su azioni. Il broker indicato è UBS Financial Services e le azioni devono essere vendute su Nasdaq con un valore di mercato aggregato approssimativo di $405,900. La dichiarazione riporta 54,562,841 azioni in circolazione e indica la data di vendita proposta come 10/09/2025. Nessun valore mobiliare è stato venduto nei tre mesi precedenti. Il firmatario attesta di non essere a conoscenza di informazioni avverse sostanziali non divulgate e segnala che il pagamento dell’esercizio è stato effettuato in contanti.
Bicara Therapeutics (BCAX) presentó un aviso de Form 144 informando una venta propuesta de 22,000 acciones ordinarias, adquiridas el mismo día al ejercer opciones sobre acciones. El corredor listado es UBS Financial Services y las acciones se venderán en Nasdaq con un valor de mercado agregado aproximado de $405,900. El informe registra 54,562,841 acciones en circulación e indica la fecha de venta propuesta como 10/09/2025. No se reportaron valores vendidos en los últimos tres meses. El presentante certifica que no tiene conocimiento de información adversa sustancial no divulgada y señala que el pago del ejercicio se realizó en efectivo.
Bicara Therapeutics (BCAX)는 Form 144 통지서를 제출하여 주식 옵션 행사로 같은 날 취득한 22,000주의 보통주 매각 제안을 공개했습니다. 브로커로 기재된 곳은 UBS Financial Services이며 매도 주식은 Nasdaq에서 거래되고 대략 총시가가 $405,900입니다. 신고서는 발행주식수로 54,562,841 주를 기록하고 제안된 매각일을 2025년 10월 9일로 표시합니다. 지난 3개월 동안 매도된 증권은 없었습니다. 신고자는 비공개인 중대한 악재정보를 모르는 것으로 확인하고, 행사 대금이 현금으로 지급되었음을 명시합니다.
Bicara Therapeutics (BCAX) a déposé un avis Form 144 révélant une vente proposée de 22 000 actions ordinaires, acquises le même jour en exerçant des options sur actions. Le courtier indiqué est UBS Financial Services et les actions doivent être vendues sur Nasdaq avec une valeur marchande totale approximative de $405,900. Le dépôt indique 54,562,841 actions en circulation et indique la date de vente proposée comme le 10/09/2025. Le dossier rapporte qu'aucune valeur mobilière n'a été vendue au cours des trois mois précédents. Le déposant atteste ne pas être au courant d'informations défavorables non divulguées et précise que le paiement de l'exercice a été effectué en numéraire.
Bicara Therapeutics (BCAX) hat eine Form 144-Mitteilung eingereicht, die einen geplanten Verkauf von 22.000 Stammaktien bekannt gibt, die am selben Tag durch Ausübung von Optionen erworben wurden. Der angegebene Broker ist UBS Financial Services und die Aktien sollen an der Nasdaq verkauft werden, mit einem ungefähren Gesamtkurswert von $405,900. Die Einreichung meldet 54.562.841 ausstehende Aktien und gibt das vorgeschlagene Verkaufsdatum als 10/09/2025 an. In den letzten drei Monaten wurden keine Wertpapiere verkauft. Der Einreicher versichert, dass er keine unbekannten wesentlichen negativen Informationen hat, und stellt fest, dass die Ausübungszahlung in Bar erfolgt ist.
Bicara Therapeutics (BCAX) قد قدمت إشعار Form 144 يكشف عن بيع مقترح لـ 22,000 من الأسهم العادية، تم الحصول عليها في اليوم نفسه من خلال ممارسة خيارات الأسهم. الوسيط المدرج هو UBS Financial Services وستتم بيع الأسهم في Nasdaq بقيمة سوقية إجمالية تقريبية قدرها $405,900. تشير الإيداع إلى وجود 54,562,841 سهمًا قائمًا وتذكر أن تاريخ البيع المقترح هو 10/09/2025. لم تُذكر أي أوراق مالية مباعة في الثلاثة أشهر الماضية. يؤكد المالك المقدم أنه لا يملك معلومات سلبية كبيرة غير معلنة ويذكر أن الدفع الناتج عن التمرين تم بالنقد.
Bicara Therapeutics (BCAX) 提交了一个 Form 144 通知，披露拟议出售 22,000 股普通股，同日通过行使股票期权获得。经纪商为 UBS Financial Services，股票将于 Nasdaq 交易，市场总值大约为 $405,900。申报显示在外流通的股票数量为 54,562,841 股，拟议的出售日期为 10/09/2025。在前3个月内未报告出售任何证券。申报人声明他们并未掌握未披露的重大不利信息，并指出行权支付以 现金 完成。
- Exercise and sale are disclosed, showing procedural transparency under Rule 144
- No prior sales in the past three months, simplifying aggregation calculations
- Cash payment for the option exercise indicates completed consideration at acquisition
- Insider sale planned of 22,000 shares (aggregate
$405,900 ), which could modestly increase selling pressure - No additional context provided about the insider's reason for sale beyond the standard attestation
Insights
Insider plans to liquidate option exercise proceeds via market sale.
The notice shows an insider exercised options and plans to sell 22,000 shares on
The main dependency is timing and execution: sale proceeds depend on market price at execution and the broker's routing. Because the position equals roughly
Procedure and attestation follow standard Rule 144 requirements.
The filer includes the required attestation that no undisclosed material adverse information exists and specifies cash payment for the option exercise on the acquisition date. The filing lists no prior sales in the past three months, which supports compliance with the aggregation rules under Rule 144.
Key items to monitor are any subsequent Form 4 or Form 5 filings that disclose actual sale prices or changes in beneficial ownership, typically filed after the transaction settles around
Bicara Therapeutics (BCAX) ha presentato una Form 144 nota che rivela una proposta di vendita di 22.000 azioni ordinarie, acquisite lo stesso giorno eseguendo opzioni su azioni. Il broker indicato è UBS Financial Services e le azioni devono essere vendute su Nasdaq con un valore di mercato aggregato approssimativo di $405,900. La dichiarazione riporta 54,562,841 azioni in circolazione e indica la data di vendita proposta come 10/09/2025. Nessun valore mobiliare è stato venduto nei tre mesi precedenti. Il firmatario attesta di non essere a conoscenza di informazioni avverse sostanziali non divulgate e segnala che il pagamento dell’esercizio è stato effettuato in contanti.
Bicara Therapeutics (BCAX) presentó un aviso de Form 144 informando una venta propuesta de 22,000 acciones ordinarias, adquiridas el mismo día al ejercer opciones sobre acciones. El corredor listado es UBS Financial Services y las acciones se venderán en Nasdaq con un valor de mercado agregado aproximado de $405,900. El informe registra 54,562,841 acciones en circulación e indica la fecha de venta propuesta como 10/09/2025. No se reportaron valores vendidos en los últimos tres meses. El presentante certifica que no tiene conocimiento de información adversa sustancial no divulgada y señala que el pago del ejercicio se realizó en efectivo.
Bicara Therapeutics (BCAX)는 Form 144 통지서를 제출하여 주식 옵션 행사로 같은 날 취득한 22,000주의 보통주 매각 제안을 공개했습니다. 브로커로 기재된 곳은 UBS Financial Services이며 매도 주식은 Nasdaq에서 거래되고 대략 총시가가 $405,900입니다. 신고서는 발행주식수로 54,562,841 주를 기록하고 제안된 매각일을 2025년 10월 9일로 표시합니다. 지난 3개월 동안 매도된 증권은 없었습니다. 신고자는 비공개인 중대한 악재정보를 모르는 것으로 확인하고, 행사 대금이 현금으로 지급되었음을 명시합니다.
Bicara Therapeutics (BCAX) a déposé un avis Form 144 révélant une vente proposée de 22 000 actions ordinaires, acquises le même jour en exerçant des options sur actions. Le courtier indiqué est UBS Financial Services et les actions doivent être vendues sur Nasdaq avec une valeur marchande totale approximative de $405,900. Le dépôt indique 54,562,841 actions en circulation et indique la date de vente proposée comme le 10/09/2025. Le dossier rapporte qu'aucune valeur mobilière n'a été vendue au cours des trois mois précédents. Le déposant atteste ne pas être au courant d'informations défavorables non divulguées et précise que le paiement de l'exercice a été effectué en numéraire.
Bicara Therapeutics (BCAX) hat eine Form 144-Mitteilung eingereicht, die einen geplanten Verkauf von 22.000 Stammaktien bekannt gibt, die am selben Tag durch Ausübung von Optionen erworben wurden. Der angegebene Broker ist UBS Financial Services und die Aktien sollen an der Nasdaq verkauft werden, mit einem ungefähren Gesamtkurswert von $405,900. Die Einreichung meldet 54.562.841 ausstehende Aktien und gibt das vorgeschlagene Verkaufsdatum als 10/09/2025 an. In den letzten drei Monaten wurden keine Wertpapiere verkauft. Der Einreicher versichert, dass er keine unbekannten wesentlichen negativen Informationen hat, und stellt fest, dass die Ausübungszahlung in Bar erfolgt ist.
FAQ
What transaction does Bicara Therapeutics (BCAX) disclose on Form 144?
How much are the proposed Bicara (BCAX) shares worth in the Form 144?
How many Bicara (BCAX) shares are outstanding according to the filing?
Was payment made for the Bicara (BCAX) option exercise?
Does the filing report other sales by the same person in the prior three months?
